Insider sales are negligible in size and follow routine director grants, no bearish signal. Monitor upcoming quarterly results for pipeline updates, as Vir's valuation is driven by clinical catalysts, not insider trading patterns.
VIR drugs
VIR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $8.77entry
- T+1 · 6mo ago +4.33%α +3.93% · $9.15
- T+5 · 5mo ago −5.93%α −2.11% · $8.25
- T+20 · 5mo ago +14.48%α +15.48% · $10.04
- T+60 · 3mo ago +28.96%α +26.46% · $11.31
Price Chart
How similar events traded
Executive Summary
Two insiders at Vir Biotechnology sold a combined $34K in open-market sales on June 1, 2026, following a wave of non-cash director stock grants on May 27. The dollar amount is trivial relative to the $1.5B market cap (0.002%), and the sales are likely liquidity-driven rather than signaling bearish conviction. The cluster is not informative.
Key Financial Metrics
Key Facts
- Director Janet Napolitano sold 3,200 shares at $9.45 for $30,240 on June 1, 2026.
- SVP/CAO Brent Sabatini sold 379 shares at $9.45 for $3,582 on June 1, 2026.
- Total open-market sales: $33,822, representing ~0.002% of Vir's $1.5B market cap.
- On May 27, 2026, six directors received non-cash stock grants totaling 128,000 shares (value $0).
- Prior 30-day insider activity: only $34K in sales, consistent with routine patterns.
Financial Impact
Total insider sales of $34K are immaterial against $1.5B market cap.
Risk Factors
- Insider sales, though small, could precede negative clinical data if insiders have material non-public information, but the dollar amount is too low to suggest this.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-VIR-1780436144771 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers